Minerva Neurosciences, Inc - Common Stock – Jahresabschlüsse (NASDAQ:NERV) | MetaTrader

Vollständige Grafik anzeigen Full chart

Nachrichten

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Minerva Neurosciences terminiert Hauptversammlung für den 3. Juni 2026

Minerva Neurosciences beruft Jim O’Connor zum Chief Business Officer

Minerva Neurosciences stellt Sicherheitsdaten für Roluperidon-Kombinationstherapie vor

H.C. Wainwright hebt Kursziel für Minerva Neurosciences wegen neuem Studiendesign an

H.C. Wainwright raises Minerva Neurosciences price target on trial design

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript

Minerva Neurosciences beruft Schizophrenie-Experten in den Verwaltungsrat

Minerva Neurosciences appoints schizophrenia expert to board of directors

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.47%

Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial - Minerva Neurosciences (NASDAQ:NERV)